Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of RSV F Vaccine in Older Adults
NCT03026348Phase 2Completed
- Sponsor
- Novavax
- Start
- Jan 2017
- Primary completion
- Apr 2017
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of RSV F vaccine + aluminum phosphate in respiratory syncytial virus infection (RSV), sponsored by Novavax. Started Jan 2017; status: completed.
02
Drugs
RSV F vaccine + aluminum phosphate
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03026348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03026348.